209 related articles for article (PubMed ID: 17571952)
21. Intravenous vs. intraprostatic administration of N-methyl-N-nitrosourea to induce prostate cancer in rats.
Schleicher RL; Fallon MT; Austin GE; Zheng M; Zhang M; Dillehay DL; Collins DC
Prostate; 1996 Jan; 28(1):32-43. PubMed ID: 8545279
[TBL] [Abstract][Full Text] [Related]
22. Growth inhibition and cytotoxicity induced by Bowman-Birk inhibitor concentrate in cisplatin-resistant human ovarian cancer cells.
Wan XS; Hamilton TC; Ware JH; Donahue JJ; Kennedy AR
Nutr Cancer; 1998; 31(1):8-17. PubMed ID: 9682243
[TBL] [Abstract][Full Text] [Related]
23. Effects of the Bowman-Birk protease inhibitor on survival of fibroblasts and cancer cells exposed to radiation and cis-platinum.
Kennedy CW; Donahue JJ; Wan XS
Nutr Cancer; 1996; 26(2):209-17. PubMed ID: 8875558
[TBL] [Abstract][Full Text] [Related]
24. Null activity of selenium and vitamin e as cancer chemopreventive agents in the rat prostate.
McCormick DL; Rao KV; Johnson WD; Bosland MC; Lubet RA; Steele VE
Cancer Prev Res (Phila); 2010 Mar; 3(3):381-92. PubMed ID: 20145190
[TBL] [Abstract][Full Text] [Related]
25. Inhibitory effects of Bifidobacterium-fermented soy milk on 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced rat mammary carcinogenesis, with a partial contribution of its component isoflavones.
Ohta T; Nakatsugi S; Watanabe K; Kawamori T; Ishikawa F; Morotomi M; Sugie S; Toda T; Sugimura T; Wakabayashi K
Carcinogenesis; 2000 May; 21(5):937-41. PubMed ID: 10783315
[TBL] [Abstract][Full Text] [Related]
26. Individual and combinatory effects of soy isoflavones on the in vitro potentiation of lymphocyte activation.
Wang W; Higuchi CM; Zhang R
Nutr Cancer; 1997; 29(1):29-34. PubMed ID: 9383781
[TBL] [Abstract][Full Text] [Related]
27. Development of the Bowman-Birk inhibitor for oral cancer chemoprevention and analysis of Neu immunohistochemical staining intensity with Bowman-Birk inhibitor concentrate treatment.
Armstrong WB; Wan XS; Kennedy AR; Taylor TH; Meyskens FL
Laryngoscope; 2003 Oct; 113(10):1687-702. PubMed ID: 14520092
[TBL] [Abstract][Full Text] [Related]
28. Effects of the Bowman-Birk inhibitor on clonogenic survival and cisplatin- or radiation-induced cytotoxicity in human breast, cervical, and head and neck cancer cells.
Zhang L; Wan XS; Donahue JJ; Ware JH; Kennedy AR
Nutr Cancer; 1999; 33(2):165-73. PubMed ID: 10368812
[TBL] [Abstract][Full Text] [Related]
29. Inhibitory effects of soy isoflavones on rat prostate carcinogenesis induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP).
Hikosaka A; Asamoto M; Hokaiwado N; Kato K; Kuzutani K; Kohri K; Shirai T
Carcinogenesis; 2004 Mar; 25(3):381-7. PubMed ID: 14656947
[TBL] [Abstract][Full Text] [Related]
30. Soy, isoflavones, and prostate cancer.
Jian L
Mol Nutr Food Res; 2009 Feb; 53(2):217-26. PubMed ID: 18985655
[TBL] [Abstract][Full Text] [Related]
31. Clinical characteristics and pharmacokinetics of purified soy isoflavones: multiple-dose administration to men with prostate neoplasia.
Fischer L; Mahoney C; Jeffcoat AR; Koch MA; Thomas BE; Valentine JL; Stinchcombe T; Boan J; Crowell JA; Zeisel SH
Nutr Cancer; 2004; 48(2):160-70. PubMed ID: 15231450
[TBL] [Abstract][Full Text] [Related]
32. Chemoprevention strategies for prostate cancer.
Bosland MC; McCormick DL; Melamed J; Walden PD; Zeleniuch-Jacquotte A; Lumey LH
Eur J Cancer Prev; 2002 Aug; 11 Suppl 2():S18-27. PubMed ID: 12570331
[TBL] [Abstract][Full Text] [Related]
33. Lycopene and soy isoflavones in the treatment of prostate cancer.
Vaishampayan U; Hussain M; Banerjee M; Seren S; Sarkar FH; Fontana J; Forman JD; Cher ML; Powell I; Pontes JE; Kucuk O
Nutr Cancer; 2007; 59(1):1-7. PubMed ID: 17927495
[TBL] [Abstract][Full Text] [Related]
34. Protective effect of Acticoa powder, a cocoa polyphenolic extract, on prostate carcinogenesis in Wistar-Unilever rats.
Bisson JF; Guardia-Llorens MA; Hidalgo S; Rozan P; Messaoudi M
Eur J Cancer Prev; 2008 Feb; 17(1):54-61. PubMed ID: 18090911
[TBL] [Abstract][Full Text] [Related]
35. Decreased growth of human prostate LNCaP tumors in SCID mice fed a low-fat, soy protein diet with isoflavones.
Aronson WJ; Tymchuk CN; Elashoff RM; McBride WH; McLean C; Wang H; Heber D
Nutr Cancer; 1999; 35(2):130-6. PubMed ID: 10693166
[TBL] [Abstract][Full Text] [Related]
36. Phase I pharmacokinetic and pharmacodynamic analysis of unconjugated soy isoflavones administered to individuals with cancer.
Takimoto CH; Glover K; Huang X; Hayes SA; Gallot L; Quinn M; Jovanovic BD; Shapiro A; Hernandez L; Goetz A; Llorens V; Lieberman R; Crowell JA; Poisson BA; Bergan RC
Cancer Epidemiol Biomarkers Prev; 2003 Nov; 12(11 Pt 1):1213-21. PubMed ID: 14652284
[TBL] [Abstract][Full Text] [Related]
37. [Influence of sodium selenite on carcinogenesis of the prostate and other organs induced by methylnitrosourea and testosterone in rats].
Bespalov VG; Panchenko AV; Murazov IaG; Chepik OF
Vopr Onkol; 2011; 57(4):486-92. PubMed ID: 22191239
[TBL] [Abstract][Full Text] [Related]
38. Prevention of carcinogenesis by protease inhibitors.
Kennedy AR
Cancer Res; 1994 Apr; 54(7 Suppl):1999s-2005s. PubMed ID: 8137328
[TBL] [Abstract][Full Text] [Related]
39. Effects of a soybean isoflavone mixture on carcinogenesis in prostate and seminal vesicles of F344 rats.
Onozawa M; Kawamori T; Baba M; Fukuda K; Toda T; Sato H; Ohtani M; Akaza H; Sugimura T; Wakabayashi K
Jpn J Cancer Res; 1999 Apr; 90(4):393-8. PubMed ID: 10363576
[TBL] [Abstract][Full Text] [Related]
40. Cancer prevention by protease inhibitors.
Kennedy AR
Prev Med; 1993 Sep; 22(5):796-811. PubMed ID: 8234219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
